Laura van’t Veer

18.1k total citations · 2 hit papers
54 papers, 4.0k citations indexed

About

Laura van’t Veer is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Laura van’t Veer has authored 54 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Cancer Research, 30 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Laura van’t Veer's work include Breast Cancer Treatment Studies (19 papers), Cancer Genomics and Diagnostics (18 papers) and HER2/EGFR in Cancer Research (8 papers). Laura van’t Veer is often cited by papers focused on Breast Cancer Treatment Studies (19 papers), Cancer Genomics and Diagnostics (18 papers) and HER2/EGFR in Cancer Research (8 papers). Laura van’t Veer collaborates with scholars based in United States, Netherlands and Belgium. Laura van’t Veer's co-authors include Martine Piccart, Fátima Cardoso, D. Gareth Evans, Emiel J. Rutgers, Mary B. Daly, Olufunmilayo I. Olopade, Timothy R. Rebbeck, Henry T. Lynch, Susan L. Neuhausen and Ellen Matloff and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Laura van’t Veer

52 papers receiving 3.9k citations

Hit Papers

Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2Mutat... 2002 2026 2010 2018 2002 2006 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2Mutations
    2002 1.0k citations Timothy R. Rebbeck, Henry T. Lynch et al. New England Journal of Medicine profile →
  2. Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
    2006 842 citations Marc Buyse, Sherene Loi et al. JNCI Journal of the National Cancer Institute profile →

Peers

Laura van’t Veer
Pierre O. Chappuis Switzerland
M. Castiglione Switzerland
Hitoshi Zembutsu Japan
Judith Balmañà Spain
J.G.M. Klijn Netherlands
Hervé Bonnefoi France
Tiffany A. Traina United States
Rinat Yerushalmi Israel
Kathleen M. Darcy United States
M. Bontenbal Netherlands
Pierre O. Chappuis Switzerland
Laura van’t Veer
Citations per year, relative to Laura van’t Veer Laura van’t Veer (= 1×) peers Pierre O. Chappuis

Countries citing papers authored by Laura van’t Veer

Since Specialization
Citations

This map shows the geographic impact of Laura van’t Veer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura van’t Veer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura van’t Veer more than expected).

Fields of papers citing papers by Laura van’t Veer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura van’t Veer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura van’t Veer. The network helps show where Laura van’t Veer may publish in the future.

Co-authorship network of co-authors of Laura van’t Veer

This figure shows the co-authorship network connecting the top 25 collaborators of Laura van’t Veer. A scholar is included among the top collaborators of Laura van’t Veer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura van’t Veer. Laura van’t Veer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liefers, Gerrit‐Jan, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐de Carpentier, et al.. (2023). Abstract GS5-10: Utility of the 70-gene MammaPrint test for prediction of extended endocrine therapy benefit in patients with early-stage breast cancer in the IDEAL Trial. Cancer Research. 83(5_Supplement). GS5–10. 6 indexed citations
2.
Basu, Amrita, et al.. (2023). Concordance between patient‐reported and physician‐documented comorbidities and symptoms among Stage 4 breast cancer patients. Cancer Medicine. 12(22). 20906–20917. 2 indexed citations
3.
Piccart, Martine, Coralie Poncet, Fátima Cardoso, et al.. (2020). Abstract GS4-05: Should age be integrated together with clinical and genomic risk for adjuvant chemotherapy decision in early luminal breast cancer? MINDACT results compared to those of TAILOR-X. Cancer Research. 80(4_Supplement). GS4–5. 4 indexed citations
4.
Magbanua, Mark Jesus M., Hope S. Rugo, Denise M. Wolf, et al.. (2018). Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clinical Cancer Research. 24(6). 1486–1499. 36 indexed citations
5.
Nanda, Rita, Minetta C. Liu, Christina Yau, et al.. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. Journal of Clinical Oncology. 35(15_suppl). 506–506. 158 indexed citations
6.
Viale, Giuseppe, Leen Slaets, Femke A. de Snoo, et al.. (2016). Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer. Breast Cancer Research and Treatment. 155(3). 463–469. 16 indexed citations
7.
Veer, Laura van’t, Laura Esserman, Ashish Sanil, et al.. (2015). DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial.. Journal of Clinical Oncology. 1 indexed citations
8.
9.
Campbell, Michael J., Denise M. Wolf, Rita A. Mukhtar, et al.. (2013). The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context. PLoS ONE. 8(10). e79114–e79114. 26 indexed citations
10.
Saghatchian, Mahasti, Stella Mook, Giancarlo Pruneri, et al.. (2013). Additional prognostic value of the 70-gene signature (MammaPrint®) among breast cancer patients with 4–9 positive lymph nodes. The Breast. 22(5). 682–690. 35 indexed citations
11.
Petrillo, Laura A., Denise M. Wolf, Ann M. Kapoun, et al.. (2012). Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Research and Treatment. 135(3). 913–922. 31 indexed citations
12.
Tian, Sun, Iris Simón, Vı́ctor Moreno, et al.. (2012). A combined oncogenic pathway signature of BRAF , KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 62(4). 540–549. 98 indexed citations
13.
Loi, Sherene, W. Fraser Symmans, John M.S. Bartlett, et al.. (2011). Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. The Lancet Oncology. 12(12). 1162–1168. 10 indexed citations
14.
Saghatchian, Mahasti, Lorenza Mittempergher, Stefan Michiels, et al.. (2011). S1-6: Characterization of Breast Cancer Distant Metastasis Based on Outcome over Time Using a Gene Expression Profiling Approach and Identification of Pathway Activities of Late Relapse.. Cancer Research. 71(24_Supplement). S1–6. 4 indexed citations
15.
Bridgewater, John, Ryan K. van Laar, Arno Floore, & Laura van’t Veer. (2008). Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British Journal of Cancer. 98(8). 1425–1430. 78 indexed citations
16.
Buyse, Marc, Sherene Loi, Laura van’t Veer, et al.. (2006). Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer. JNCI Journal of the National Cancer Institute. 98(17). 1183–1192. 842 indexed citations breakdown →
17.
Domchek, Susan M., Tara M. Friebel, Susan L. Neuhausen, et al.. (2006). Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. The Lancet Oncology. 7(3). 223–229. 216 indexed citations
18.
Dai, Hongyue, Laura van’t Veer, John R. Lamb, et al.. (2005). A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients. Cancer Research. 65(10). 4059–4066. 207 indexed citations
19.
Schooten, Frederik‐Jan van, Silvio De Flora, Francesco D’Agostini, et al.. (2002). Effects of Oral Administration of N-Acetyl-l-cysteine. Cancer Epidemiology and Prevention Biomarkers. 11(2). 167–175. 2 indexed citations
20.
Rebbeck, Timothy R., Henry T. Lynch, Susan L. Neuhausen, et al.. (2002). Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2Mutations. New England Journal of Medicine. 346(21). 1616–1622. 1025 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre O. Chappuis Breakdown of academic impact, for papers by M. Castiglione Breakdown of academic impact, for papers by Hitoshi Zembutsu Breakdown of academic impact, for papers by Judith Balmañà Breakdown of academic impact, for papers by J.G.M. Klijn Breakdown of academic impact, for papers by Hervé Bonnefoi Breakdown of academic impact, for papers by Tiffany A. Traina Breakdown of academic impact, for papers by Rinat Yerushalmi Breakdown of academic impact, for papers by Kathleen M. Darcy Breakdown of academic impact, for papers by M. Bontenbal
Rankless by CCL
2026